Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SEINRLF 55 Forward PE Ratio is 118.86 as of Jul. 19, 2026. GuruFocus rates INRLF with a GF Score™ of 55/100 and a GF Value™ of $2.68 (Fairly Valued). The stock has 6 warning signs investors should review. Among 355 Biotechnology companies, Valneva SE ranks worse than 90.7% on this metric.
Valneva SE's Forward PE Ratio for today is 118.86.
Valneva SE (OTCPK:INRLF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Valneva SE Forward PE Ratio Related Terms
Valneva SE Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Valneva SE's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE Forward PE Ratio Chart
Valneva SE Annual Data
Trend
Forward PE Ratio
Valneva SE Quarterly Data
Forward PE Ratio
INRLF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Valneva SE's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Valneva SE's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Valneva SE (INRLF) has a Forward PE Ratio of 118.86 as of Jul. 19, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #322 out of 355 companies in the Biotechnology industry, placing it in the top 90.7%.
Is Valneva SE's Forward PE Ratio too high?
Valneva SE's current Forward PE Ratio is 118.86. The Biotechnology industry median Forward PE Ratio is 22.27. Valneva SE's value of 118.86 is 433.7% above this industry median. Based on the distribution chart, Valneva SE ranks #322 out of 355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valneva SE has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #322 out of 355 companies for Forward PE Ratio. This places Valneva SE in the lower half of its industry. The industry median Forward PE Ratio is 22.27. Valneva SE's value of 118.86 is 433.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.27, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current Forward PE Ratio of 118.86 is 433.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Forward PE Ratio is 118.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.68, compared to a current price of $2.62 — trading 2.2% below its estimated fair value. The current Forward PE Ratio is 118.86 and 433.7% above the Biotechnology industry median of 22.27. Valneva SE's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Valneva SE (INRLF), the current Forward PE Ratio is 118.86 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 2.2% below its estimated GF Value™ of $2.68.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for INRLF:
Forward PE Ratio: 118.86
GF Value™: $2.68 vs. price of $2.62 (2.2% below fair value)
Industry Position: 433.7% above the Biotechnology median (#322 of 355)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
55GF Score
Get the complete analysis for INRLF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
